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FORMULATIONS AND METHODS TO
PROTOZOAL MYELOENCEPHALITIS

Because of the uncertainty of the oral bioavailability and
steady state concentrations of these agents in the CNS, and
the fact that other treatment regimens may be only

BACKGROUND OF THE INVENTION

apicomplexistatic, the availability of a highly lipid-soluble
agent With a long plasma half-life, good CNS entry

TREAT AND PREVENT EQUINE

characteristics, and the ability to kill S. neurona in the CNS
Would be a useful addition to the anti-EPM therapeutic

Equine ProtoZoal Myeloencephalitis (EPM) is the leading
infectious neurologic disease of American horses. Consis
tently safe and effective treatments for this disease are not
available. Conventional therapy relies on relatively non

speci?c drug/medication combinations; these approaches

armamentarium. Additionally, current therapeutic
10

are only partially effective and relapses and/or adverse
reactions are common.

provides these features, Whereas the previous treatments do

EPM is a NeW World disease and is the most common

infectious neurological disease of horses in the Western

not
15

hemisphere. It is caused by an “apicomplexan” parasite
called Sarcocystis neurona (S. HQZU‘OI’LLZ), Which cycles natu

The present treatment methods utiliZe triaZine-based

anticoccidials, preferably diclaZuril, to prevent and treat
EPM, Without the side effects of previous EPM treatments.

rally betWeen opossums and birds. The horse is an aberrant
host, becoming exposed When it consumes infectious mate
rial from opossum feces. In the horse, S. neurona makes its

approaches are associated With signi?cant adverse responses
in treated animals, one of Which is dysbacteriosis resulting
in lethal diarrhea and anemia. Amore effective and less toxic
agent Would be highly desirable. The present invention

20

Way to the brain and spinal cord, Where it proliferates and

EPM and coccidiosis are both caused by “apicomplexan”
parasites; hoWever, coccidiosus does not affect the CNS as
does EPM.

TriaZine-based compounds have previously been used in
the prophylaxis of coccidiosis in poultry in Canada, Europe,

causes clinical disease.

The epidemiology and economic signi?cance of S. neu

and South America. Vanparijs et. al., 129 Vet. Rec. 339

rona infection is substantial. In endemic areas in the U.S.,
(1991); Driessen et. al., 72Aust. Vet. 139 (1995). DiclaZuril
over 40% of horses are seropositive. Of these, a small 25 has been used to treat coccidiosus in turkeys, ducks, quail,

percentage are clinically affected. Of animals clinically
affected, 30—40% reportedly fail to respond to current

guinea-foWl, pheasants, partridges, mice, rats, dogs, rabbits,

therapy, and some of these animals die. Better and more

(1994); Lindsay et al., 81(2) J. Parisitol. 315 (1995); and

cattle, and horses. Lindsay et al., 55 Am. J. Vet. Res. 976

effective prophylactic and therapeutic modalities are

required.

30

The economic loss in performance horse breeding is
likely more substantial than the above ?gures suggest. The

although neither Equine ProtoZoal Myelitis nor S. neurona
are mentioned. Moreover, diclaZuril, in particular is gener
35

unrecorded, these losses may be signi?cant.
EPM occurs Wherever opossums are found. All cases of

EPM therefore trace to Western hemisphere exposure, and

the incidence of EPM is likely greatest in areas With high

40

opossum populations. HoWever, clinical cases of EPM are

found throughout the World, because horses Who become
infected With S. neurona While in opossum territories may be

transported elseWhere.
The localiZation of S. neurona in the brain and spinal cord

4,952,570 also discloses the use of triaZine-based com

pounds (including diclaZuril) to treat protoZoal infections,

?gures presented refer to clinically observable infections
only. Subclinical infections Will shoW only at the racetrack,
Where Well-bred animals may fail to perform to their genetic
potential because of subclinical infection With EPM. While

Vanparijs et al., 32 Vet. Parisitol. 109 (1989). US. Pat. No.

ally considered non-absorbable by the small intestine, and
systemic treatment of protoZoal infections not possible.
DiclaZuril has been shoWn to be active against Neospora
caninum, another apicomplexan organism, in vitro but not
yet in vivo. Lindsay et. al., 55 Amer. V et. J. R. 926 (1994)
and Dubey and Lindsay, 67 Vet. Parisitol. 1 (1996). Dicla
Zuril has also been shoWn to be effective against intestinal
Eimeria spp. in many avian hosts and against intestinal and
hepatic coccidiosis in rabbits. Vanparijs et. al., 32 Vet.

Parisitol. 109 (1989).
45

In other Work, diclaZuril has been used in the prophylaxis
and treatment of experimental T gondii infection in mice.

is a critical obstacle to treatment of EPM. The brain and

While diclaZuril alone or in combination With

spinal cord are immunologically privileged; as such,

pyrimethamine protected mice against death folloWing

immune responses are likely less effective in the brain than
elseWhere. Current treatments, as detailed beloW, do not
directly kill S. 11614701161,‘ as such they often fail to effect a
“cure.” The present treatment method directly kills S.

tion did not prevent tissue cyst formation, including brain

inoculation With T gondii, diclaZuril, alone or in combina
tissue cyst formation in surviving mice. Based on this Work

in mice, Lindsay concluded that combinations of diclaZuril

11614701161, making it dramatically different from previous

and pyrimethamine may be bene?cial in the treatment of

treatments.

toxoplasmosis in man and animals Lindsay et. al., 81(2) J.
Parisitol. 315 (1995). More importantly, the mice in these
experiments died from pneumonia and hepatitis; there is no
evidence from the Lindsay experiments to suggest that
diclaZuril is effective in the treatment of encephalitis. The

Previous therapy for BPM consists of administration of

55

various combinations of sulfonamides, trimethoprim and

pyrimethamine (Daraprim). HoWever, many horses relapse
When therapy ceases, probably because the current therapies
do not cross the blood/brain barrier reliably and/or attack the

organism directly. These agents only hinder proliferation of

60

data shoW that diclaZuril did not prevent tissue cyst forma
tion in the CNS.

S. neurona and do not kill it. The inability of current
treatments to kill S. neurona likely contributes to the sig

SUMMARY OF THE INVENTION

ni?cant relapse rate after therapy ceases.
One of the major concerns about current therapeutic

It is therefore an object of the present invention to provide
formulations and methods to prevent or treat EPM compris

approaches to EPM is the difficulty in maintaining simulta
neous minimum inhibitory concentrations (MICs) of
pyrimethamine, trimethoprim and sulfonamides in the CNS.

65

ing administering a pharmaceutically acceptable amount of
a triaZine-based anti-coccidial such as claZuril, diclaZuril,
toltraZuril or letraZuril. Treatments and formulations Which

5,883,095
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include a combination of other therapies With the presently
disclosed therapy for treatment of active infection are also
Within the scope of the present invention.
De?nitions:
“EPM” means equine protoZoal myelitis or equine pro

horse With EPM tends to shoW the folloWing clinical/clinical

chemistry signs:
The horse Will: be grade 3—4 on a ?ve point scale

neurological exam; asymmetric in muscle vitality; positive
for EPM on spinal tap by Western blot, have exhibited
relapse after current treatment, With all other potential

toZoal myeloencephalitis or a disease Which manifests as

symptoms of either equine protoZoal myelitis or equine
protoZoal myeloencephalitis, or closely related
apicomplexan-based neurological diseases of horses.

causes of ataxia excluded.

The triaZine-based anticoccidials can be purchased from
commercial sources, such as Janssen Pharmaceutica in Bel

gium (claZuril, letraZuril and diclaZuril) or Bayer AG in
Leverkusen, Germany (toltraZuril). HoWever, one skilled in

DETAILED DESCRIPTION OF THE
INVENTION

the art is aWare hoW to synthesiZe these compounds de novo

The present invention provides formulations of triaZine
based anticoccidials for the use in preventing and/or treating
EPM. For preventative therapy, a horse-feed based formu
lation is preferred. Most preferred is a horse-feed formula

using conventional methods.

tion Which comprises diclaZuril. For treatment of clinical or
sub-clinical EPM, an oral formulation is preferred. A most
preferred oral formulation is one Which is administered as a
paste. Speci?cally, an oral formulation Which comprises a
triaZine-based anticoccidial, is administered as a paste, and

one triaZine-based anti-coccidial to the feed as it is made or

Formulations can be made using conventional formula

tion technology. Horse food composition is Well knoWn in
the art. The present formulation comprises adding at least
after it is made, so as to provide an overall composition

consistent With the dosages necessary for prophylaxis or
20

treatment, depending on the use. For instance, for a feed
Which Would be useful as a prophylactic treatment, the

folloWing formulation could be made (all percentages are by
Weight, not less than the numbers given):

further comprises other desirable therapeutics, such as anti

in?ammatories, sulfonamides, trimethoprim,
pyrimethamine and/or other anti-protoZoals is considered
Within the scope of the present invention.
The present invention also provides methods to treat EPM
in a horse in need of such treatment, comprising adminis
tering a pharmaceutically acceptable amount of a triaZine

25

Diclazuril

based anti-coccidial. Preferred is a method to treat EPM

using claZuril, diclaZuril, toltraZuril or letraZuril. Most pre

30

ferred is a method to treat EPM using toltraZuril or dicla
Zuril. Also preferred is a method to treat EPM using a

triaZine-based anti-coccidial in combination With an anti

0.0002—0.002%

protein

10%

fat
?ber
calcium

3.5%
6.0%
0.6%

phosphorus

0.45%

copper
Zinc
selenium

35 ppm
140 ppm
0.6 ppm

vitamin A

3,000 IU/lb

in?ammatory agent and/or previously-knoWn treatment
modalities.

A feed Which Would be useful as a treatment of clinical

Moreover, since horses are a dead-end host for S.
11614701161, triaZine-based anticoccidials may be administered
prophylactically to horses likely to come in contact With the

EPM, could have the folloWing composition, for instance:

organism, Without the risk of producing a triaZine-based
anti-coccidial-resistant S. neurona in the environment.

Toltrazuril
40

Therefore, the present invention also provides methods to
prevent S. neurona infection in horses comprising adminis
tering a prophylactic amount of a triaZine-based anticoc
cidial. Preferred is a method to prevent S. neurona infection

by administering claZuril, diclaZuril, toltraZuril or letraZuril.
Most preferred is a method to prevent S. neurona infection
using toltraZuril or diclaZuril.
The treatments provided are able to completely kill all S.
neurona present in the animal. Aconsiderable portion of the

45

0.1—0.5%

protein

10%

fat
?ber
calcium

3.5%
6.0%
0.6%

phosphorus

0.45%

copper
Zinc
selenium

35 ppm
140 ppm
0.6 ppm

vitamin A

3,000 IU/lb

HoWever, a preferred embodiment of a feed formulation for
50

treating EPM Would be:

recovery from the clinical symptoms of infection, hoWever,
occurs after treatment, because clearance of dead S. neurona
Diclazuril

organisms, reduction of in?ammatory response and repair of
damaged neurons normally takes up to a year. Exercise and

anti-in?ammatory medication play a positive role in the

55

repair process.
In order to diagnose a horse With clinical EPM, it should
be both CSF positive for S. neurona antibodies and shoW a
history and clinical signs consistent With EPM. Other non
S. neuronal-based causes of neuropathy must also be

60

0. 25 %

protein

10%

fat
?ber
calcium

3.5%
6.0%
0.6%

phosphorus

0.45%

copper
Zinc
selenium

35 ppm
140 ppm
0.6 ppm

vitamin A

3,000 IU/lb

excluded. Afurther sign is response and/or relapse folloWing
standard therapy, if the information is available.
The folloWing is provided as a guideline for diagnosing
EPM, although those in the art are familiar With differential

diagnosis techniques. Moreover, treatment of mis-diagnosed

Simple oral formulations may also be made using avail
able Clinacox, oats and molasses, or Clinacox, oats, sWeet

feed, bran and Water, for example. Moreover, any formula

horses pursuant to the present methods Would not result in

tion Which comprises a triaZine-based anti-coccidial and
prior EPM treatment methods is considered Within the scope

resistant S. neurona for reasons previously discussed. A

of the present invention. For example, sulfonamides, trime

5,883,095
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thoprim and pyrimethamine (Daraprim) added to the above

if required, but can be administered in the folloWing com

formulations are Within the purview of the present invention.
Of course, the formulation Would have to be adjusted for the

mon dosage range: 1.5—10 grams of drug per day. HoWever,

appropriate pharmaceutically-acceptable percentage of ?nal

the scope of the invention. Moreover, the dosage can be time
release, Which can be any of the above, except that it is

any EPM-effective dose or duration of treatment is Within

concentration of all ingredients.
Moreover, since paste formulations are the generally
preferred mode of administration of orally-bioavailable
compounds, a paste formulation acceptable to horses is

formulated so as to release a certain dose continuously or

intermittently over a period of time. It is also a preferred
embodiment to administer the drug as an injection, one or
more times per day, at the same dose as above.

hereby provided. Any carriers or excipients, preferably those
Which enhance absorption, can also be included in the
present formulations. One such absorption-enhancing car
rier is lactose. Other carriers knoWn in the art may also be

10

treatment for the blood and cerebro-spinal ?uid concentra
tions of diclaZuril to attain steady-state. The present inven
tion includes a method to treat EPM Wherein steady-state is

used. SWeetners or other ?avor-enhancers may be used as

Well.

Some examples of suitable carriers, excipients and dilu
ents include lactose, dextrose, sucrose, sorbitol, mannitol,

15

starches, gum acacia, calcium phosphate, alginates,
tragacanth, gelatin, calcium silicate, microcrystalline
cellulose, polyvinylpyrrolidone, cellulose, Water syrup,

methyl cellulose, methyl-and propylhydroxybenZoates, talc,

20

magnesium stearate and mineral oil. The formulations can

additionally include lubricating agents, Wetting agents,
emulsifying and suspending agents, preserving agents,
sWeetening agents or ?avoring agents. The formulations
may be made so as to provide quick, sustained or delayed
release of the active ingredient after administration to the

Because diclaZuril has a relatively long plasma half-life in
horses, it takes about 5—7 days of a standard 5 mg/kg/21 day

25

acheived by administering larger doses (“loading doses”) in
the ?rst day or ?rst feW days of treatment. For example, it
may be bene?cial to give 5—10 grams per day for the ?rst day
or ?rst feW days to severely affected horses to attain steady
state concentrations quicker than at loWer concentrations.
Not all horses Will require such an accelerated treatment,
although such treatment for all horses Would not be dam
aging for those Who do not require it.
The dosage for prophylaxis of EPM can be less than that
necessary for treating EPM, but may be the same, depending
on the need of the individual horse. A typical preventative
dose of the triaZine-based anti-coccidials herein disclosed

Would be 0.3—0.15 mg/kg/day, preferably 0.5—0.1 mg/kg/

patient by employing procedures Well knoWn in the art.
The formulations are preferably formulated in a unit

day, hoWever, it can be administered via a feed formulation

dosage form, each dosage containing from about 0.1 to 10%
active ingredient by Weight, more usually about 0.25 to 5%
of the active ingredient. The term “unit dosage form” refers
to physically discrete unites suitable as unitary dosages for
mammals, each unit containing a predetermined quantity of
active material calculated to produce the desired therapeutic

of 0.0002%—0.002% active ingredient, or 1 mg/kg'1 in feed

effect, in association With a suitable pharmaceutical carrier.
Formulations of the present invention could therefore also

30

or 200 g of 0.5% Clinacox pre-mix per ton of feed as Well.
Horses can be fed formulations herein described on a

schedule consistent With their needs.
In summary, a full treatment plan for an animal With EPM

Would comprise the folloWing sequential approaches: a.)
35

reduce of the local in?ammatory response in the CNS; b.)

contain acceptable amounts of the folloWing ingredients:

kill the S. neurona in the CNS; and c.) provide nerve
strengthening stimulus. In order to reduce the local in?am

grain products, molasses products, plant protein products,

matory response, NSAID medication is effective; especially

soybean oil, calcium carbonate, salt, attapulgite clay, dical
cium phosphate, sodium selenite, propionic acid, choline
chloride, tetrasodium pyrophosphate, calcium pantothenate,
vitamin E supplement, ribo?avin supplement, vitamin B-12
supplement, niacin supplement, vitamin A supplement, vita
min D-3 supplement, ferrous carbonate, manganous oxide,
Zinc oxide, copper sulfate, magnesium oxide, calcium iodate

40

45

and cobalt carbonate.
These compounds may be administered in any formula
tion Which alloWs EPM to be treated. For feed formulations,
it is important to give enough feed to the animal to ensure
to take into account Wasted feed that is left in the feeding

steroidal or non-steroidal anti-in?ammatory medication dur
ing recovery may also be bene?cial.

area and inaccessible to the animal. Moreover, the com

transdermally, sublingually, transmucosally, via tablet, pill,
poWder, loZenge, sachet, cachet, elixir, suspension,

to give higher doses initially, to increase the rate of steady
state concentrations, or to give larger doses (ie. 2.5—7.5
grams per day) for a longer period of time (ie. 1 to 2 Weeks).
To optimiZe neuromuscular circuit function, exercise seems
to speed recovery. Daily roundpen exercise and having the
animal turned out as much as possible Will be bene?cial in
most cases, so long as the animal tolerates it. Further either

ingestion of the required dose. For example, it is necessary
pounds and/or formulations may be administered via any
acceptable method or route. For example, the compounds
and/or formulations may be administered in the feed,
through formulation With the feed, or via liquid or solid (ie.
poWder) added at the time of feeding. The compounds
and/or formulations can also be administered intravenously,

if started tWo days before the triaZine-based anti-coccidial is
started. Banamine, phenylbutaZone or similar drugs seem to
be optimal. In order to kill S. Neurona, 2.5 grams of
diclaZuril per day for three Weeks seems to be suf?cient and
may be optimal. In some severe cases, it may be appropriate

EXAMPLES
55

Example 1
The Disposition And Pharmacokinetics Of ToltraZuril.
The folloWing Were initial studies to determine the bio

availability of toltraZuril in non-EPM infected horses. Five
horses Were given 5 grams/ 1000 lbs body Weight toltraZuril
60

by stomach tube and blood levels Were determined at

emulsion, solution, syrup, aerosol (as a solid or in a liquid

various time periods after administration.

medium), ointment, soft or hard gelatin capsule, suppository,
sterile injectable solution, sterile packaged poWder and
transdermal patch.

With peak plasma concentrations occurring at 24 hours after
drug administration. Additionally, this agent Was shoWn to

The dosage for treatment of EPM Will preferably vary

according to the Weight of the horse (ie. 3—15 mg/kg/day,
preferably 5—10 mg/kg/day), for from 20—40 days or longer

ToltraZuril Was very Well-absorbed after administration,

65

have a long plasma half-life (54 hours). The long plasma half
life facilitated maintainenance of plasma concentrations at

consistently high (ug/ml) concentrations for Weeks. Under

5,883,095
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these conditions of continuous high plasma concentrations,

continued to improve and no clinical signs suggestive of

the opportunity for the drug to enter the CNS Was maxi
miZed. Pharmacokinetic projections based on these kinetics

relapse or re-infection With S. neurona have been observed.
TWelve months after treatment ended, this mare Was
returned to an experimental breeding herd on the UK farm,

Were that single daily doses of 5 gms/horse Will yield plasma
concentrations of about 30 pig/ml of toltraZuril after 15 days.
Administered every second day, this same dose yields steady
state plasma concentrations of about 15 pig/ml.

essentially neurologically normal. Additionally, this mare
has not relapsed or re-infected, despite being in an infectious
environment. Clinically, and effectively, this mare continues
to improve and has shoWn no signs of relapse. At tWelve
months post treatment, this mare is clinically sound and her

Example 2
This trial involved a 12 year old mare With a chronic
relapsing case of EPM. This mare Was admitted to the Dept.

of Clinical Medicine at a major Mid-Western University
Teaching Hospital With an admitting diagnosis of severe
neurologic dysfunction. The mare Was mildly depressed and
“shaky”, With ataxia, severe proprioceptive de?cits and
numerous super?cial bruises and abrasions. A cerebrospinal

10

Example 3
15

?uid analysis Was “positive” for antibodies to S. neurona.
Based on the clinical symptoms, a presumptive diagnosis of
EPM Was made. Treatment consisted of oral pyrimethamine

(0.3 mg/kg, sid; Daraprim) and trimethoprimsulfamethox

20

The mare Was discharged With a diagnosis of EPM With
bra. It Was recommended that treatment continue for 30 to

25

60 days. Prior to discharge, the horse had great dif?culty

30

A fourteen year old mare, about grade 3, had relapsed on

fend for herself at pasture With other horses, Was unable to
graZe, could not Walk in a straight line, and Was rapidly
losing condition. Later, the mare Was severely ataxic, very

Weak and partially spastic, shoWing little ?exion of the

previously-knoWn therapies. She Was recently admitted, and
given three Weeks diclaZuril, through Clinacox, as above.
Her condition improved considerably during treatment and
her post-treatment progress is being closely Watched. Five
months after treatment ended this mare has not relapsed.

40

Example 5

examination, the mare Was diagnosed as a classic severe,
progressive case of EPM. The condition of the mare Was
45

for any therapeutic agent.
After 21 days of treatment With Clinacox (0.5% premix
(5g/kg of feed (2.5 g/day)) Pharmacia & Upjohn Animal
Health, 40 Centennial Road, Orangeville, Ontario, LDW

A valuable tWo-year old colt in training Was admitted at
grade 3 on the neurological scale. This horse Was unusual in
that its symptoms included several cranial nerve signs,
indicating that at least some of its EPM lesions Were in the
brain. Prior to treatment, this animal had dif?culty ambu

lating and leaned against the stall Wall; prognosis for this
animal Was extremely guarded. This animal shoWed clear
clinical improvement by the end of the ?rst Week of

3T3) there Was a marked amelioration of neurological signs
and a concomitant improvement in physical condition. At

treatment, at Which time light round pen exercise Was

started. At the end of the second Week, light exercise under

the end of the treatment, the mare shoWed some neurologic
regression, and the clinical condition Was not as good as
earlier in the treatment. Treatment Was stopped 21 days after

start due to lack of available Clinacox. Despite the partial

(July 1997) this gelding has continued to improve and has
not relapsed.

Example 4

impaired so that she Was con?ned to a stall. She could not 35

deteriorating and she Was considered a signi?cant challenge

since treatment ended, he has improved dramatically, pre
sumably due reduction in the in?ammatory response and to
the neurological scale. Six months after treatment ceased

poll. PhenylbutaZone Was prescribed, presumably for the

hocks and difficulty in pivoting. This mare Was both serum
and CSF “positive” for S. neurona on Western blot analysis
at the time of donation to UK. FolloWing a neurological

after treatment started, he fell in his stall, could not get up,
and had to be slung. He completed the three Weeks treatment
at 2.5 g of diclaZuril/day as Clinacox and remained in the
sling for several Weeks thereafter. At times, this horse Was so
Weak that euthanasia Was seriously considered. HoWever,

nerve regeneration once the organism Was eliminated. He
Was turned out in a paddock, and Was last graded as 1.5 on

Walking, and When exiting the stall she reared and fell on her
local trauma and to reduce the in?ammatory response in the
CNS.
Ayear later, this horse Was shipped to Kentucky. She Was
accepted as an experimental donation at the University of
Kentucky. The mare Was sufficiently neurologically

A four year old gelding Was treated for 3 Weeks With
Clinacox as indicated in Example 2. The horse Was a grade

3.5 neurological (on scale of 1—5, 5 most severe) When
admitted, but had deteriorated prior to treatment Shortly

aZole (15 mg/kg, bid) and intravenous DMSO With ?uids for
three days.
presumptive secondary trauma at the second cervical verte

most recent CSF tap suggest that the amount of anti- S.
neurona antibody in her CSF is declining. This mare is likely
to go CSF negative for S. neurona eventually.

a rider Was started. Administration of diclaZuril Was contin
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ued for a fourth Week in this animal because of its training
schedule.

regression in clinical signs in the later phases of therapy the

Four months after therapy ceased, this animal has

condition of this mare has steadily improved since treatment
ceased.
Eighty-three days after the end of treatment, the mare Was

improved from grade 3 neurological (barely able to stand),

clinically sound, active and fending for herself in pasture.
Although some muscle atrophy and minor signs of perma
nent neurologic damage remain, the mare has shoWn no sign
of relapse since treatment ceased nine months ago. This
mare hoWever, has not gone “CSF negative” for S. neurona,
and When tested three months post treatment, she Was still

CSF positive for antibodies to this agent Nevertheless, since
treatment ceased, the clinical condition of this mare has

to mild signs on one hind limb. This colt continues to
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improve daily and has shoWn no signs of relapse, and has
returned to full training.

Example 6
Four 10,000 pound mares Were dosed With 500 g Clinacox

(2.5 g diclaZuril) by stomach tube and plasma concentrations
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of the agent Were folloWed. Plasma concentrations of Cli
nacox peak at about 1.0 pig/ml at 24 hours after dosing and
decline With a half-life of about 45 hours. Pharmacokinetic

5,883,095
10
3. A method of claim 1, Wherein the triaZine-based
anti-coccidial is toltraZuril.
4. A method of claim 1, Wherein the triaZine-based
anti-coccidial is diclaZuril.
5. A method of claim 4, Which further comprises admin

projections based on these data shoW that daily oral doses of

ClinacoX should yield steady state plasma concentrations of
diclaZuril by siX days after dosing and that trough plasma
concentrations of diclaZuril are not less than 85% of peak

plasma concentrations.
These consistently high plasma concentrations of
diclaZuril, the apparently high oral bioavailability of this
agent and its apparently high lipid solubility makes it

istering a pharmaceutically-effective anti-in?ammatory
agent.
6. A method of claim 5, Which further comprises eXercis

ing the horse daily.

extremely likely that therapeutically signi?cant cerebrospi

7. A method to prevent S. neurona infection in horses

nal ?uid concentrations of this agent in animals are attained
and maintained on the standard therapeutic schedule.

More recently, CSF concentrations of 200—250 mg/ml
diclaZuril in horses have been detected. These ?ndings of
signi?cant steady state concentrations of diclaZuril in CSF
support and eXtend the eXamples of oral bioavailability of
these agents, their ability to penetrate the central nervous
system and their apparent therapeutic efficacy in the treat

ment of equine protoZoal myeloencephalitis.
What is claimed is:
1. A method to treat EPM in a horse is need of such

treatment, comprising administering a pharmaceutically
effective amount of a triaZine-based anti-coccidial.

2. A method of claim 1, Wherein the triaZine-based
anti-coccidial is chosen from the group consisting of

claZuril, diclaZuril, toltraZuril and letraZuril.
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comprising administering a prophylactic amount of a
triaZine-based anticoccidial.
8. A method of claim 7, Wherein the triaZine-based
anticoccidial is chosen from the group consisting of claZuril,
diclaZuril, toltraZuril and letraZuril.
9. A method of claim 8, Wherein the triaZine-based
anticoccidial is diclaZuril.
10. A method to kill S. neurona in horses comprising

administering S. neuronal-killing amount of diclaZuril.
11. A horse-feed formulation useful to treat equine pro

toZoal myeloencephalitis comprising a triaZine-based anti
coccidial and an anti-protoZoal agent selected from the

group consisting of: sulfonamide, trimethoprim and

pyrimethamine.

